

NEW BENZOXAZINE DERIVATIVES USEFUL AS INTEGRIN RECEPTOR ANTAGONISTS

5 Field of the Invention

The present invention relates to novel compounds which bind to the integrin receptor $\alpha_v\beta_3$, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents.

10

Background of the Invention

Integrins are a group of cell surface glycoproteins which mediate cell adhesion and therefore are useful mediators of cell adhesion interactions which occur during various biological processes. Integrins are heterodimers composed of noncovalently linked α and β polypeptide subunits. Currently eleven different α subunits have been identified and six different β subunits have been identified. The various α subunits can combine with various β subunits to form distinct integrins.

20 The integrin identified as $\alpha_v\beta_3$ (also known as the vitronectin receptor) has been identified as an integrin which plays a role in various conditions or disease states including tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy including macular
25 degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration (e.g. restenosis arteriosclerosis). Additionally, it has been found that such agents would be useful as antivirals, antifungals and antimicrobials. Thus, compounds which selectively inhibit or antagonize $\alpha_v\beta_3$ would be beneficial for treating such conditions.

30

It has been shown that the $\alpha_v\beta_3$ integrin and other α_v containing integrins bind to a number of Arg-Gly-Asp (RGD) containing matrix macromolecules.

Compounds containing the RGD sequence mimic extracellular matrix ligands so as to bind to cell surface receptors. However, it is also known that RGD peptides in general are non-selective for RGD dependent integrins. For example, most RGD peptides which bind to $\alpha_v\beta_3$ also bind to $\alpha_v\beta_5$, $\alpha_v\beta_1$ and $\alpha_{IIb}\beta_3$. Antagonism of platelet $\alpha_{IIb}\beta_3$ (also known as the fibrinogen receptor) is known to block platelet aggregation in humans. In order to avoid bleeding side-effects when treating the conditions or disease states associated with the integrin $\alpha_v\beta_3$, it would be beneficial to develop compounds which are selective antagonists of $\alpha_v\beta_3$ as opposed to $\alpha_{IIb}\beta_3$.

The compounds of this invention are therefore selective $\alpha_v\beta_3$ integrin antagonists. The present invention includes compounds which inhibit the respective integrin and also includes pharmaceutical compositions comprising such compounds. The present invention further provides for methods for treating or preventing conditions mediated by the $\alpha_v\beta_3$ receptor in a mammal in need of such treatment comprising administering a therapeutically effective amount of the compounds of the present invention and pharmaceutical compositions of the present invention. Administration of such compounds and compositions of the present invention inhibits angiogenesis, tumor metastasis, tumor growth, osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, retinopathy, macular degeneration, arthritis, periodontal disease, smooth muscle cell migration, including restenosis and arteriosclerosis, and viral diseases.

Tumor cell invasion occurs by a three step process: 1) tumor cell attachment to extracellular matrix; 2) proteolytic dissolution of the matrix; and 3) movement of the cells through the dissolved barrier. This process can occur repeatedly and can result in metastases at sites distant from the original tumor.

Seftor et al. (Proc. Natl. Acad. Sci. USA, Vol. 89 (1992) 1557-1561) have shown that the $\alpha_v\beta_3$ integrin has a biological function in melanoma cell invasion. Montgomery et al., (Proc. Natl. Acad. Sci. USA, Vol. 91 (1994) 8856-60) have demonstrated that the integrin $\alpha_v\beta_3$ expressed on human melanoma cells promotes a survival signal, protecting the cells from apoptosis. Mediation of the

tumor cell metastatic pathway by interference with the $\alpha_v\beta_3$ integrin cell adhesion receptor to impede tumor metastasis would be beneficial.

Brooks et al. (Cell, Vol. 79 (1994) 1157-1164) have demonstrated that antagonists of $\alpha_v\beta_3$ provide a therapeutic approach for the treatment of
5 neoplasia (inhibition of solid tumor growth) since systemic administration of $\alpha_v\beta_3$ antagonists causes dramatic regression of various histologically distinct human tumors.

The adhesion receptor integrin $\alpha_v\beta_3$ was identified as a marker of angiogenic blood vessels in chick and man and therefore such receptor plays a
10 critical role in angiogenesis or neovascularization. Angiogenesis is characterized by the invasion, migration and proliferation of smooth muscle and endothelial cells. Antagonists of $\alpha_v\beta_3$ inhibit this process by selectively promoting apoptosis of cells in neovasculature. The growth of new blood
vessels, or angiogenesis, also contributes to pathological conditions such as
15 diabetic retinopathy including macular degeneration (Adamis et al., Amer. J. Ophthalmol., Vol. 118, (1994) 445-450) and rheumatoid arthritis (Peacock et al., J. Exp. Med., Vol. 175, (1992), 1135-1138). Therefore, $\alpha_v\beta_3$ antagonists would be useful therapeutic agents for treating such conditions associated with
neovascularization (Brooks et al., Science, Vol. 264, (1994), 569-571).

It has been reported that the cell surface receptor $\alpha_v\beta_3$ is the major
20 integrin on osteoclasts responsible for attachment to bone. Osteoclasts cause bone resorption and when such bone resorbing activity exceeds bone forming activity it results in osteoporosis (loss of bone), which leads to an increased number of bone fractures, incapacitation and increased mortality. Antagonists
25 of $\alpha_v\beta_3$ have been shown to be potent inhibitors of osteoclastic activity both *in vitro* [Sato et al., J. Cell. Biol., Vol. 111 (1990) 1713-1723] and *in vivo* [Fisher et al., Endocrinology, Vol. 132 (1993) 1411-1413]. Antagonism of $\alpha_v\beta_3$ leads to decreased bone resorption and therefore restores a normal balance of bone forming and resorbing activity. Thus it would be beneficial to provide
30 antagonists of osteoclast $\alpha_v\beta_3$ which are effective inhibitors of bone resorption and therefore are useful in the treatment or prevention of osteoporosis.


The role of the $\alpha_v\beta_3$ integrin in smooth muscle cell migration also makes it a therapeutic target for prevention or inhibition of neointimal hyperplasia which is a leading cause of restenosis after vascular procedures (Choi et al., J. Vasc. Surg. Vol. 19(1) (1994) 125-34). Prevention or inhibition of neointimal

5 hyperplasia by pharmaceutical agents to prevent or inhibit restenosis would be beneficial.

White (Current Biology, Vol. 3(9)(1993) 596-599) has reported that adenovirus uses $\alpha_v\beta_3$ for entering host cells. The integrin appears to be required for endocytosis of the virus particle and may be required for
 10 penetration of the viral genome into the host cell cytoplasm. Thus compounds which inhibit $\alpha_v\beta_3$ would find usefulness as antiviral agents.

Summary of the Invention


15 The present invention as a first object provides compounds of the following formula (I)




(I)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein

20 G is selected from the group consisting of:



wherein Q is NH or O and Q' is H, C₁-C₆ alkyl, phenyl, or phenyl-C₁-C₄-alkyl;



wherein **R'** and **R''** are independently H or C₁-C₄ alkyl;

B is a C₁-C₄ alkyl or a C₂-C₄ alkenyl;

A is CH₂, O, S(O)_n wherein n is zero, 1 or 2, NH, a group CON(R''') or N(R''')CO wherein R''' is hydrogen or CH₃;

R1 is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃;


X is C=O or completes a single bond;

R2 is selected from the group consisting of H, C₁-C₄ alkyl, C₃-C₇ cycloalkyl, C₁-C₄-alkylcycloalkyl; aryl unsubstituted or optionally substituted by one to three substituents independently selected from halogen, CF₃, C₁-C₄ alkyl, hydroxy and C₁-C₄ alkoxy; aralkyl; and C₅-C₇ monocyclic heteroaryl ring containing one to three heteroatoms chosen from O, S, and N, unsubstituted or optionally substituted by one to three substituents independently selected from halogen, CF₃, C₁-C₄ alkyl, hydroxy and C₁-C₄ alkoxy;

Y is (CH₂)_n wherein n is 1 or 2;

R is hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, aryl or aryl-C₁-C₄ alkyl.

With the proviso that m can not be 0 when G is :



wherein Q' is H and Q is O and X is (C=O)_m.

The present invention includes within its scope all possible isomers, stereoisomers and optical isomers and their mixtures, and the bioprecursors or metabolites of the compounds of formula (I).

It is another object of the invention to provide pharmaceutical compositions comprising compounds of the Formula I. Such compounds and compositions are useful in selectively inhibiting or antagonizing the $\alpha_v \beta_3$ integrin and therefore in another embodiment the present invention relates to a method of selectively inhibiting or antagonizing the $\alpha_v \beta_3$ integrin. The invention further involves treating or inhibiting pathological conditions associated therewith such as osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis, including tumor angiogenesis, retinopathy including macular degeneration and diabetic retinopathy, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, smooth muscle cell migration and restenosis in a mammal in need of such treatment. Additionally, such pharmaceutical agents are useful as antiviral agents, and antimicrobials.

Detailed Description

The present invention relates to a class of compounds represented by the Formula I, described above.

A halogen atom is preferably chlorine or fluorine.

The alkyl, alkoxy, alkenyl and alkynyl groups and the alkylene and alkenylene chains may be branched or straight groups or chains, respectively.

A C₃-C₇ cycloalkyl group is, e.g., a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, in particular cyclopropyl, cyclopentyl and cyclohexyl.

A C₁-C₄ alkylcyclopropyl group is a C₁-C₄ alkyl group linked to a C₃-C₇ cycloalkyl group, such as, for instance, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopentylethyl, cyclohexylethyl and the like.

An aryl group is, e.g., an aromatic C₆-C₂₀ mono- or polynuclear moiety, typically phenyl or naphthyl.

A C₅-C₇ monocyclic heteroaryl ring as defined above is preferably a C₅-C₆ heteromonocyclic ring, in particular selected from pyridine, pyrazine,

pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole.

- An aralkyl group is e.g. benzyl or phenethyl, in which the phenyl ring is optionally substituted by one to three substituents independently chosen from
- 5 halogen, hydroxy, CF₃, C₁-C₄ alkyl and C₁-C₄ alkoxy.
- A C₂-C₄ alkenyl group is preferably an allyl group.
- A C₁-C₆ alkyl group is preferably a C₁-C₄ alkyl group.
- A C₁-C₄ alkyl group is preferably a methyl or ethyl group.
- A C₂-C₄ alkynyl group is preferably an ethynyl group.
- 10 A C₁-C₄ alkoxy group is preferably methoxy, ethoxy, propoxy and butoxy.

- Examples of pharmaceutically acceptable salts of the compounds of the invention are those with either inorganic bases, such as sodium, potassium, calcium and aluminum hydroxides, or organic bases, such as lysine, arginine, N-
- 15 methyl-glucamine, triethylamine, triethanolamine, dibenzylamine, methylbenzylamine, di-(2-ethyl-hexyl)-amine, piperidine, N-ethylpiperidine, N,N-diethylaminoethylamine, N-ethylmorpholine, β-phenethylamine, N-benzyl-β-phenethylamine, N-benzyl-N,N-dimethylamine and the other acceptable organic amines, as well as the salts with inorganic acids, e.g. hydrochloric, hydrobromic,
- 20 sulphuric and phosphoric acids and with organic acids, e.g. citric, tartaric, maleic, malic, fumaric, trifluoroacetic, methanesulphonic and ethanesulphonic acids.
- As stated above, the present invention also includes within its scope pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I), i.e. compounds which have a different formula to
- 25 formula (I) above, but which nevertheless upon administration to a human being are converted directly or indirectly *in vivo* into a compound of formula (I).


- A further object of the present invention is to provide a compound of formula (I), as herein defined, or a pharmaceutically acceptable salt thereof, for
- 30 use in a method of treatment of the human or animal body by therapy, in particular for treating conditions mediated by the $\alpha_v\beta_3$ integrin.

The object of the present invention is also to provide a pharmaceutical

composition comprising a pharmaceutically acceptable carrier and/or diluent and as an active principle a compound of formula (I), as herein defined, or a pharmaceutically acceptable salt thereof.

- 5 The present invention also provides the use of a compound of formula (I), as defined above, in the preparation of a medicament having $\alpha_v\beta_3$ integrin inhibiting or antagonizing activity.


- 10 The present invention also provides a method for treating conditions mediated by the $\alpha_v\beta_3$ integrin in a mammal, including humans, in need of such treatment comprising administering to said mammal an effective $\alpha_v\beta_3$ inhibiting or antagonizing amount of a compound of formula (I)









(I)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

G is selected from the group consisting of



- 20 wherein Q is NH or O and Q' is H, C₁-C₆ alkyl, phenyl, or phenyl- C₁-C₄-alkyl;



wherein **R'** and **R''** are independently H or C₁-C₄alkyl;

B is a C₁-C₄ alkyl or a C₂-C₄ alkenyl;

A is CH₂, O, S(O)_n wherein n is zero, 1 or 2, NH, a group CON(R''') or N(R''')CO wherein R''' is hydrogen or CH₃;

5 **R**₁ is selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, and CF₃;

X is C=O or completes a single bond;


R₂ is selected from the group consisting of H, C₁-C₄ alkyl, C₃-C₇ cycloalkyl, C₁-C₄-alkylcycloalkyl; aryl unsubstituted or optionally substituted by one

10 to three substituents independently selected from halogen, CF₃, C₁-C₄ alkyl, hydroxy and C₁-C₄ alkoxy; aralkyl; and C₅-C₇ monocyclic heteroaryl ring containing one to three heteroatoms selected from O, S, and N, unsubstituted or optionally substituted by one to three substituents independently selected from halogen, CF₃, C₁-C₄ alkyl, hydroxy and C₁-C₄ alkoxy;

15 **Y** is (CH₂)_n wherein n is 1 or 2;

R is hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, aryl or aryl-C₁-C₄ alkyl.


20 With the proviso that m can not be 0 when **G** is :



wherein Q' is H and Q is O and **X** is (C=O)_m.







25 More specifically, the present invention provides a method for inhibiting bone resorption, treating osteoporosis, inhibiting humoral hypercalcemia of malignancy, treating Paget's disease, inhibiting tumor metastasis, inhibiting neoplasia (solid tumor growth), inhibiting angiogenesis including tumor angiogenesis, treating diabetic retinopathy, arthritis, psoriasis and periodontal disease, and inhibiting smooth muscle cell migration including restenosis.

30 Preferred compounds of the invention are those wherein, in formula (I), **G** is selected from the group consisting of



wherein Q is NH or O and Q' is H, C₁-C₆ alkyl, phenyl, or phenyl- C₁-C₄-alkyl;

5




wherein R' is as defined above;

10 B, X, R, R₁ and A are as defined above;

R₂ is a phenyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole or isoxazole ring, unsubstituted or optionally substituted by one or two substituents selected from halogen, CF₃, C₁-C₄ alkyl, OH and C₁-C₄ alkoxy;



15 Y is CH₂.

With the proviso that m can not be 0 when G is :



20 wherein Q' is H and Q is O and X is (C=O)_m.

Most preferred compounds of the invention are those wherein, in formula (I), G is selected from the group consisting of



25

B, X, R, R1 and A are as defined above;

R2 is a phenyl or pyridine ring unsubstituted or optionally substituted by one or two substituents selected from halogen, CF₃, C₁-C₄ alkyl, OH and C₁-C₄ alkoxy;

Y is CH₂; and a pharmaceutically acceptable salts, prodrug or ester thereof.

Examples of specific preferred compounds according to the invention are the following:

10

(4-phenyl-6-{{3-(2-pyridinylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{{4-(2-pyridinylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

15

(4-phenyl-6-{{5-(2-pyridinylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-phenyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

20

(4-phenyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{{3-(2-pyridinylamino)propanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

25

(4-methyl-6-{{4-(2-pyridinylamino)butanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{{5-(2-pyridinylamino)pentanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

30

(4-methyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl} amino}-3,4-dihydro-2H-1,4-

- benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
5 (4-cyclopropylmethyl-6-[[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
10 (4-cyclopropylmethyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
15 (4-cyclohexylmethyl-6-[[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
20 (4-cyclohexylmethyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
25 (4-benzyl-6-[[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-benzyl-6-[[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
30 (4-benzyl-6-[[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-benzyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

- (4-benzyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 5 (4-benzoyl-6-{{3-(2-pyridinylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-{{4-(2-pyridinylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-{{5-(2-pyridinylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 10 (4-benzoyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 15 (4-benzoyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{3-(2-pyridinylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{4-(2-pyridinylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 20 (4-nicotinoyl-6-{{5-(2-pyridinylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 25 (4-nicotinoyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- [4-phenyl-6-{{2-(2-pyridinylamino)ethylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;
- 30 [4-phenyl-6-{{3-(2-pyridinylamino)propylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;
- [4-phenyl-6-{{4-(2-pyridinylamino)butylamino}carbonyl}-3,4-dihydro-2H-1,4-

benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{2-(1H-imidazol-2-ylamino)ethylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{3-(1H-imidazol-2-ylamino)propylamino}carbonyl}-3,4-dihydro-2H-

5 1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{4-(1H-imidazol-2-ylamino)butylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

A further object of the present invention is a combined method of treatment
10 of cancer or of controlling the growth of the neoplasm in mammals, including humans, suffering from cancer, said method comprising administering

- 1) a compound of the invention, or a pharmaceutically acceptable salt thereof, and
- 15 2) an additional antitumor agent, in amounts and close enough together in time sufficient to produce a therapeutically useful effect.

The present invention also provides a product containing a compound of the invention, or a pharmaceutically acceptable salt thereof, and an effective
20 antineoplastic amount of additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

The object of the present invention is to provide the use of a compound of formula (I), as herein defined, or a pharmaceutically acceptable salt thereof, in
25 the manufacture of a medicament having $\alpha_v\beta_3$ integrin inhibiting or antagonizing activity for controlling the growth of the neoplasm in a patient undergoing a simultaneous, separate or sequential treatment with another antitumor agent.

The combination preparation according to the invention can also include
30 combination packs or compositions in which the constituents are placed side by side and can therefore be administered simultaneously, separately or sequentially to one and the same human being. Accordingly, the antineoplastic agent and a compound according to the present invention may be present

within a single or distinct container means.

In the combined preparations, pharmaceutical compositions and methods of treating, according to the present invention, the antineoplastic agent
5 may comprise 1 to 4, preferably 1, 2 or 3, antineoplastic drugs, in particular a single antineoplastic drug.

As used herein, "controlling the growth" of the neoplasm refers to slowing, interrupting, arresting or stopping its growth and it does not necessarily
10 indicate a total elimination of the neoplasm. It is believed that prolonging the survivability of a patient, beyond being a significant advantageous effect in and of itself, also indicates that the condition is beneficially controlled to some extent.

15 The term "antineoplastic agent" is meant to comprise both a single antineoplastic cytotoxic drug and "cocktails", i.e. mixtures of such drugs, according to the clinical practice.

As used herein, the term "effective antineoplastic amount" refers to an
20 amount which is effective, upon single or multiple dose administration to the patient, in controlling the growth of the neoplasm or in prolonging the survivability of the patient beyond that expected in the absence of such treatment.

25 An antineoplastic agent, according to the invention, is preferably selected from the group comprising: an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

30 An antineoplastic topoisomerase II inhibitor is preferably:

- a) an anthracycline compound e.g. doxorubicin (including liposomal formulations) daunomycin, methoxy-morpholino-doxorubicin, epirubicin (including liposomal formulation), idarubicin and nemorubicin; and

- b) an anthraquinone compound e.g. mitoxantrone and losoxantrone; and
- c) a podophillotoxine compound e.g. etoposide and teniposide.

An antimicrotubule agent is preferably:

- 5 a) a taxane compound e.g. paclitaxel (including liposomal formulations) and docetaxel; and
- b) a vinca alkaloid e.g. vinblastine and vinorelbine.

10 An alkylating agent is preferably cyclophosphamide, ifosfamide, chlorambucil, melphalan and PNU 159548 (C. Geroni et al., Proc. Am. Assoc. Cancer Res 39, p223, 1998 (Abstr. #1517)).

15 An antineoplastic antimetabolite agent is e.g. 5-fluorouracil, capecitabine, gemcitabine, methotrexate and edatrexate.

An antineoplastic topoisomerase I inhibitor is e.g. topotecan, irinotecan, 9-nitrocamptothecin and PNU 166148 (Compound A1 in WO 99/17804).

20 An antineoplastic agent is in particular epirubicin, doxorubicin, liposome-encapsulated doxorubicin, docetaxel, paclitaxel and liposome-encapsulated paclitaxel.

25 Particularly preferred preparations, pharmaceutical compositions and methods of treating, according to the present invention, are those comprising a) 1, 2 or 3 antineoplastic agents selected from epirubicin, doxorubicin, idarubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide and vinorelbine, and b) a compound of the invention or a pharmaceutically acceptable salt thereof.

30 The effective antineoplastic amounts of the various antineoplastic agents are well known and appreciated in the art.

For example, an effective antineoplastic amount of vinblastine may vary from about 3 mg/m² to about 10 mg/m².

An effective antineoplastic amount of doxorubicin may vary from about

20 mg/m² to about 100 mg/m².

An effective antineoplastic amount of epirubicin may vary from about 20 mg/m² to about 200 mg/m².

5 An effective antineoplastic amount of idarubicin may vary from about 1 mg/m² to about 50 mg/m².

An effective antineoplastic amount of mitoxantrone may vary from about 10mg/m² to about 20 mg/m².

An effective antineoplastic amount of paclitaxel may vary from about 100 mg/m² to about 300 mg/m².

10 An effective antineoplastic amount of docetaxel may vary from about 50 mg/m² to about 100 mg/m².

An effective antineoplastic amount of vinorelbine may vary from about 15 mg/m² to about 30 mg/m².

15 An effective antineoplastic amount of cyclophosphamide may vary from about 100 mg/m² to about 1500 mg/m².

An effective antineoplastic amount of melphalan may vary from about 1 mg/m² to about 10 mg/m².

An effective antineoplastic amount of 5-fluorouracil may vary from about 100 mg/m² to about 1000 mg/m².

20 An effective antineoplastic amount of capecitabine may vary from about 10 mg/m² to about 1000 mg/m².

An effective antineoplastic amount of methotrexate may vary from about 10 mg/m² to about 1000 mg/m².

25 An effective antineoplastic amount of topotecan may vary from about 1 mg/m² to about 5 mg/m².

An effective antineoplastic amount of irinotecan may vary from about 50 mg/m² to about 350 mg/m².

30 In effecting treatment of a patient afflicted with a disease state described above a compound of formula (I) of the invention can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, it can be administered orally, subcutaneously, intraperitoneally, intramuscularly, intravenously, transdermally,

and the like. Oral or intramuscular administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular circumstances, including the disease state to be treated, the stage of the disease, the form of administration of the selected cytotoxic agent and the manner of co-administration selected.

The selected antineoplastic agent can be administered by the appropriate route and dosing schedule as is well known and accepted for the particular agent. For example, epirubicin, doxorubicin, idarubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide and vinblastine can be administered intravenously. Idarubicin and cyclophosphamide can also be given orally.

In the combined preparations, pharmaceutical compositions, method of treating and therapeutic uses, according to the present invention, specific preferred compounds of the invention are the following:

- (4-phenyl-6-[[3-(2-pyridinylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-phenyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-phenyl-6-[[5-(2-pyridinylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-phenyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-phenyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-phenyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-methyl-6-[[3-(2-pyridinylamino)propanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-methyl-6-[[4-(2-pyridinylamino)butanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-methyl-6-[[5-(2-pyridinylamino)pentanoyl] amino]-3,4-dihydro-2H-1,4-

- benzoxazin-2-yl)acetic acid;
(4-methyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-methyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
5 (4-methyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
10 (4-cyclopropylmethyl-6-[[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
15 (4-cyclopropylmethyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclopropylmethyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
20 (4-cyclohexylmethyl-6-[[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
25 (4-cyclohexylmethyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-cyclohexylmethyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
30 (4-cyclohexylmethyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
(4-benzyl-6-[[3-(2-pyridinylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

- (4-benzyl-6-[[4-(2-pyridinylamino)butanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzyl-6-[[5-(2-pyridinylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 5 (4-benzyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 10 (4-benzoyl-6-[[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-[[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-[[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 15 (4-benzoyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 20 (4-benzoyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-[[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 25 (4-nicotinoyl-6-[[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-[[5-(2-pyridinylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 30 (4-nicotinoyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-

benzoxazin-2-yl)acetic acid;

[4-phenyl-6-{{2-(2-pyridinylamino)ethylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{3-(2-pyridinylamino)propylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{4-(2-pyridinylamino)butylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;


[4-phenyl-6-{{2-(1H-imidazol-2-ylamino)ethylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{3-(1H-imidazol-2-ylamino)propylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-{{4-(1H-imidazol-2-ylamino)butylamino}carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

The compounds of the invention and the salt thereof can be prepared by and in analogy to the following processes.

A compound of formula (I) wherein A, B, X, Y, R, R1 and R2 are as defined above, and G is as defined under d) to g), can be obtained by reacting a compound of formula (II)




(II)

wherein A, B, X, Y, R, R1 and R2 are as defined above, and G₁ is represented by G, as defined above under d) to g) wherein one or more nitrogens are protected with suitable protective groups, such as, for instance, carbobenzyloxy or *t*-butoxycarbonyl, removable with a suitable reducing agent, or with an acid, such as trifluoroacetic acid or hydrochloric or hydrobromic acid.

A compound of formula (II) can be obtained by:

1) reacting a compound of formula (III)



5

wherein X, Y, R, R1 and R2 are as defined above, and A₁ is NH(R'''), wherein R''' is as defined above, with a compound of formula (IV)



(IV)

- 10 wherein G₁ and B are as defined above, in the presence of a suitable condensing agent such as, for instance, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, Mukayama's reagent or other condensing agents known to those skilled in the art, thus
- 15 obtaining a compound of formula (II) wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is N(R''')CO; or

2) reacting a compound of formula (III), wherein X, Y, R, R1 and R2 are as defined above, and A₁ is OH, with a compound of formula (V)

20



(V)

wherein G₁ and B are as defined above, and W is Cl, Br, I, OH, OSO₂C₁-C₄-alkyl or OSO₂Aryl, thus obtaining a compound of formula (II) wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is O; or


25

3) reacting a compound of formula (III), wherein X, Y, R, R1 and R2 are as defined above, and A₁ is SH, with a compound of formula (V), wherein G₁ and B are as defined above and W is different from OH, thus obtaining a compound of formula (II) wherein G₁, B, X, Y, R, R1 and R2 are as defined

30 above, and A is S; or

- 4) reacting a compound of formula (III), wherein X, Y, R, R₁ and R₂ are as defined above, and A₁ is NH(R'''), with a compound of formula V, wherein G₁ and B are as defined above and W is different from OH, thus obtaining a
 5 compound of formula (II) wherein G₁, B, X, Y, R, R₁ and R₂ are as defined above, and A is N(R'''); or


- 5) reacting a compound of formula (VI)



(VI)

- wherein X, Y, R, R₁ and R₂ are as defined above, with a compound of formula (IV), as defined above, using a suitable condensing agent such as, for instance, polyphosphoric acid or ethyl polyphosphate or trifluoroacetic anhydride or trifluoromethanesulfonic acid or other agents known to those skilled in the art,
 15 followed by treatment of the resulting product with a reducing agent such as hydrogen in presence of a suitable metal catalyst, such as palladium on carbon, or triethylsilane in trifluoroacetic acid, thus obtaining a compound of formula (II) wherein G₁, B, X, Y, R, R₁ and R₂ are as defined above, and A is CH₂; or

- 20 6) reacting a compound of formula (VII)



(VII)

- wherein X, Y, R, R₁ and R₂ are as defined above, with a compound of formula (VIII)



(VIII)


- wherein G₁, B and R''' are as defined above, in the presence of suitable

condensing agents such as those described under 1), thus obtaining a compound of formula (II) wherein G_1 , B, X, Y, R, R1 and R2 are as defined above, and A is $CON(R''')$.

- 5 7) reacting a compound of formula (II), wherein G_1 , B, X, Y, R, R1 and R2 are as defined above, and A is S, with a suitable oxydizing agent, such as $NaIO_4$, oxone, H_2O_2 or a peracid, thus obtaining a compound of formula (II) wherein G_1 , B, X, Y, R, R1 and R2 are as defined above, and A is $S(O)_n$ wherein n is 1 or 2, i.e. A is a sulfoxide or a sulfone group.

10

A compound of formula (I) wherein A, B, X, Y, R, R1 and R2 are as defined above, and G is as defined under b), c) or under a), wherein Q is different from oxygen, can be obtained by reacting a compound of formula (IX)



15

(IX)

wherein A, B, X, Y, R, R1 and R2 are as defined above, with a suitable guanilating agent such as, for example, *N,N'*-di-*t*-butoxycarbonyl-*N''*-triflylguanidine or 2-methylthio-2-imidazoline hydriodide or 2-methylthio-1,4,5,6-tetrahydropyrimidine hydriodide, followed by removal of the protecting groups in the case where the guanilating agent is *N,N'*-di-*t*-butoxycarbonyl-*N''*-triflylguanidine.

20


A compound of formula (I) wherein A, B, X, Y, R, R1 and R2 are as defined above, and G is as defined under a), wherein Q is oxygen, can be obtained by reacting a compound of formula (IX), as defined above, with an inorganic cyanate, such as sodium or potassium or ammonium cyanate, or with an isocyanate of formula $Q'NCO$, wherein Q' is as described above.

25

A compound of formula (IX,) in turn, can be obtained in analogy to the processes described under 1) to 6) by:

30

8) reacting a compound of formula (III)



(III)

where X, Y, R, R1 and R2 are as defined above, and A₁ is NH(R'''), wherein R'''
 5 is as defined above, with a compound of formula (X)



(X)

wherein B is as defined above and Z₁ is a suitable amino protecting group such
 as, for instance, benzyloxycarbonyl, *tert*-butoxycarbonyl or other protecting
 10 groups listed in GREENE, T.W., WUTS, P.G.M. Protective group in organic
 synthesis, Wiley, 1999, followed by removal of the amino protecting group, thus
 obtaining a compound of formula (IX) wherein B, X, Y, R, R1 and R2 are as
 defined above, and A is N(R''')CO; or,

15 9) reacting a compound of formula (III), wherein X, Y, R, R1 and R2 are
 as defined above, and A₁ is OH, with a compound of formula (XI)



(XI)

wherein B, W and Z₁ are as defined above, followed by removal of the amino
 20 protecting group, thus obtaining a compound of formula (IX) wherein B, X, Y, R,
 R1 and R2 are as defined above, and A is O; or

10) reacting a compound of formula (III), wherein X, Y, R, R1 and R2 are
 as defined above, and A₁ is SH, with a compound of formula (XI), wherein Z₁
 25 and B are as defined above and W is different from OH, followed by removal of
 the amino protecting group, thus obtaining a compound of formula (IX) wherein
 B, X, Y, R, R1 and R2 are as defined above, and A is S; or


11) reacting a compound of formula (III), wherein X, Y, R, R1 and R2 are
 30 as defined above, and A₁ is SH, with a compound of formula (XI), wherein Z₁

and B are as defined above and W is different from OH, followed by treatment with a suitable oxydizing agent, such as oxone, NaIO_4 , H_2O_2 or a peracid and subsequent removal of the amino protecting group, thus obtaining a compound of formula (IX) wherein B, X, Y, R, R1 and R2 are as defined above, and A is

5 S(O)_n wherein n is 1 or 2; or

12) reacting a compound of formula (III), wherein X, Y, R, R1 and R2 are as defined above, and A_1 is $\text{NH(R}'')$, with a compound of formula (XI), wherein Z_1 and B are as defined above and W is different from OH, followed by removal
10 of the amino protecting group, thus obtaining a compound of formula (IX) wherein B, X, Y, R, R1 and R2 are as defined above, and A is $\text{N(R}'')$; or


13) reacting a compound of formula (VI)



(VI)


15 wherein X, Y, R, R1 and R2 are as defined above, with a compound of formula (X), as defined above, in the presence of a suitable condensing agent such as those described under 5), followed by treatment of the resulting product with a reducing agent such as triethylsilane in trifluoroacetic acid, and removal of the
20 amino protecting group thus obtaining a compound of formula (IX) wherein B, X, Y, R, R1 and R2 are as defined above, and A is CH_2 ; or

14) reacting a compound of formula (VII)



(VII)

25 wherein X, Y, R, R1 and R2 are as defined above, with a compound of formula (VIII)



(XII)

- wherein Z_1 , B and R''' are as defined above, in the presence of a suitable condensing agent such as those described under 1), followed by removal of the amino protecting group, thus obtaining a compound of formula (IX) wherein B, X, Y, R, R1 and R2 are as defined above, and A is $\text{CON}(\text{R}''')$.

- The compounds of formula (III), (VI), and (VII) can be prepared from the properly substituted *o*-aminophenol, according to general synthetic methods for the preparation of 1,4-benzoxazines.

Additionally, a compound of formula (I) can be obtained by a process which comprises:

- i) converting a compound of formula (I) into another compound of formula (I), or separating a single isomer of a compound of formula (I) from a mixture thereof, or converting a compound of formula (I) into a salt thereof, or converting a salt of a compound of formula (I) into a free compound of formula (I);
- ii) reacting a compound of formula I wherein G, A, B, X, Y, R1 and R2 are as defined above and R is different from hydrogen with aqueous acids or aqueous bases thus obtaining a compound of formula I wherein R is hydrogen;

- In particular, the compounds described above can be prepared as exemplified in the following procedures.

- In a typical procedure, a compound of formula I, as defined above, can be obtained by treatment of a compound of formula II, as defined above, with hydrogen in the presence of a suitable catalyst, such as palladium on carbon, in a solvent like a lower alcohol or dioxane, or by treatment with trifluoroacetic acid or hydrobromic acid in acetic acid, followed by isolation of the product by chromatography.

In a typical procedure for the preparation of a compound of formula II, as described above, to a solution of a compound of formula III, wherein X, Y, R, R1 and R2 are as defined above, and A₁ is NH(R'''), wherein R''' is as defined above, and a compound of formula IV, as defined above, in a solvent like dichloromethane, tetrahydrofuran, dioxane or dimethylformamide are added 4-dimethylaminopyridine and a suitable condensing agent, such as *N,N'*-dicyclohexylcarbodiimide or *N,N'*-diisopropylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate or Mukayama's reagent. The reaction mixture is stirred at a temperature from about 0°C to room temperature for 2 to 18 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is N(R''')CO.

In a typical procedure for the preparation of a compound of formula II, as described above, to a solution of a compound of formula III, wherein X, Y, R, R1 and R2 are as defined above, and A₁ is OH, triphenylphosphine and a compound of formula V, as defined above and wherein W is OH, in a solvent like toluene or tetrahydrofuran or dichloromethane, a solution of an alkyl azodicarboxylate in toluene or tetrahydrofuran or dichloromethane is added and the mixture stirred at a temperature from room temperature to about 40 °C for 1 to 6 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is O.

In a typical procedure for the preparation of a compound of formula II, as described above, a solution of a compound of formula III, wherein X, Y, R, R1 and R2 are as defined above, and A₁ is SH, in a solvent like tetrahydrofuran, acetone, dimethylformamide or dimethylsulfoxide or a lower alcohol, is treated with an organic or an inorganic base such as, for instance, triethylamine or potassium or sodium carbonate or potassium or sodium hydroxide, or sodium hydride, then a compound of formula V, as described above and wherein W is different from OH, is added. The reaction mixture is stirred at a temperature

from room temperature to about 40°C for 1 to 8 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G_1 , B, X, Y, R, R1 and R2 are as defined above, and A is S.

- 5 In a typical procedure for the preparation of a compound of formula II, as described above, to a solution of a compound of formula III, wherein X, Y, R, R1 and R2 are as defined above, and A_1 is $NH(R''')$, and an organic or an inorganic base such as, for instance, triethylamine or diisopropylethylamine or potassium or sodium carbonate, in a solvent like tetrahydrofuran, acetone,
10 dimethylformamide or dimethylsulfoxide or a lower alcohol, a compound of formula V, as described above and wherein W is different from OH, is added. The reaction mixture is stirred at a temperature from room temperature to about 40°C for 1 to 8 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G_1 , B, X, Y, R, R1 and R2 are
15 as defined above, and A is $N(R''')$.

- In a typical procedure for the preparation of a compound of formula II, as defined above, a compound of formula VI, wherein X, Y, R, R1 and R2 are as defined above, and a compound of formula IV, as defined above, are mixed with
20 polyphosphoric acid or ethyl polyphosphate or trifluoroacetic anhydride or trifluoromethanesulfonic acid and the mixture is stirred at a temperature from room temperature to 140°C, for 1 to 6 hours. The reaction is stopped by pouring into water, the product is extracted with a solvent like ethyl acetate or dichloromethane and the product is isolated by column chromatography. The
25 product is then reduced by treatment with hydrogen in the presence of palladium on carbon, in a solvent like dioxane or a lower alcohol, thus obtaining a compound of formula II, wherein G_1 , B, X, Y, R, R1 and R2 are as defined above, and A is CH_2 .

- 30 In a typical procedure for the preparation of a compound of formula II, as defined above, to a solution of a compound of formula VII, wherein X, Y, R, R1 and R2 are as defined above, and a compound of formula VIII, as defined above, in a solvent like dichloromethane, tetrahydrofuran, dioxane or

dimethylformamide are added 4-dimethylaminopyridine followed by a suitable condensing agent, such as *N,N'*-dicyclohexylcarbodiimide or *N,N'*-diisopropylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate or Mukayama's reagent. The reaction mixture is stirred at a temperature from about 0°C to room temperature and for 2 to 18 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is CON(R''').

10 In a typical procedure for the preparation of a compound of formula II, a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is S, is treated with 30% aqueous H₂O₂ in a lower alcohol as a solvent, or with a peracid or with dimethyldioxirane, at a temperature from room temperature to about 50°C for 1 to 6 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is SO₂.

20 In a typical procedure for the preparation of a compound of formula II, a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is S, is treated with NaIO₄ in water and methanol, or acetone and water, or with oxone in a mixture of methanol and water as a solvent, at a temperature from about -30°C to room temperature for 1 to 4 hours. The product is then isolated by column chromatography, thus obtaining a compound of formula II, wherein G₁, B, X, Y, R, R1 and R2 are as defined above, and A is SO.

30 In a typical procedure for the preparation of a compound of formula I, wherein A, B, X, Y, R, R1, R2 are as defined above, and G is as defined under b), c) or under a) wherein Q is different from oxygen and Q' is hydrogen, a compound of formula IX, as defined above, is reacted with a suitable guanylation agent, like *N,N'*-di-*t*-butoxycarbonyl-*N''*-triflylguanidine or 2-methylthio-2-imidazoline hydriodide or 2-methylthio-1,4,5,6-tetrahydropyrimidine hydriodid in a solvent like dichloromethane, tetrahydrofuran, dioxane or a lower

alcohol, at a temperature from room temperature to reflux, for 24 to 72 hours. The solvent is then evaporated and the residue is treated with trifluoroacetic acid when the reaction is performed with *N,N'*-di-*t*-butoxycarbonyl-*N''*-triflyl-guanidine. The product is then isolated by chromatography.

5

In typical procedure for the preparation of a compound of formula I, wherein A, B, X, Y, R, R1, R2 are as defined above, and G is as defined under a) wherein Q is oxygen and Q' is hydrogen, a compound of formula IX, as defined above, is reacted with a cyanate salt, as e.g. an ammonium or sodium or potassium salt, in a solvent such as acetic acid or water, at a temperature from about 50°C to about 100°C, for 2 to 12 hours. The product is isolated by extraction or by filtration and is then purified by column chromatography.

10

In typical procedure for the preparation of a compound of formula I, wherein A, B, X, Y, R, R1, R2 are as defined above, and G is as defined under a) wherein Q is oxygen and Q' is different from hydrogen, a compound of formula IX, as defined above, is reacted with an isocyanate of formula Q'NCO, wherein Q' is as defined above, in a solvent like dichloromethane, acetonitrile, tetrahydrofuran, dioxane or toluene, in the presence of triethylamine, at a temperature from room temperature to about 100°C and for 4 to 24 hours. The resulting compound is isolated by column chromatography.

15

20

The preparation of a compound of formula IX, as described above, can be performed according to the processes described under 8) to 14) and applying the procedures described above.

25

The preparation of 1,4-benzoxazines III, VI, and VII from the properly substituted *o*-aminophenol can be carried out following known procedures as described, for instance, in METHODS OF ORGANIC CHEMISTRY (HOUBEN-WEIL), volume E 9a, pp. 141-177, George Thieme Verlag, Stuttgart 1997, or by suitable modifications of such methods as known to those skilled in the art.

30

Additionally, in a typical procedure, a compound of formula I, as defined above and wherein R is hydrogen, is obtained by treatment of a compound of

formula I, as defined above and wherein R is different from hydrogen, with a mixture of an aqueous acid, like hydrochloric acid, and a lower alcohol or dioxane, at a temperature from room temperature to about 40°C, for 1 to 24 hours. Alternatively, a compound of formula I, as defined above and wherein R is different from hydrogen, is treated with an aqueous base, like sodium or lithium or potassium hydroxide, in a solvent like methanol or ethanol or dioxane, at a temperature from room temperature to about 40°C, for 1 to 24 hours. The solution is then treated with an acid and the compound filtered.

- 10 The optional salification of a compound of formula I as well as the conversion of a salt into the free compound and the separation of a mixture of isomers into the single isomers may be carried out by conventional methods. For example, the separation of optical isomers can be carried out by salification with an optically active base or acid and by subsequent fractional crystallisation of the diastereoisomeric salts, followed by recovering of the optically active isomeric acids or bases, respectively.

- 20 The compounds of formula I and the pharmaceutically acceptable salts thereof are herein defined as the “compounds of the present invention”, the “compounds of the invention” and/or the “active principles of the pharmaceutical compositions of the invention”.

Pharmacology

- 25 The compounds of the invention are selective integrin receptor inhibitors or antagonists, in particular they are inhibitors or antagonists of the $\alpha_v\beta_3$ integrin receptors. The specific inhibiting or antagonist activity of the compounds of the invention is shown for instance by the fact that they are active in *in vitro* solid phase $\alpha_v\beta_3$ -vitronectin binding assay, as described below.

30

$\alpha_v\beta_3$ -vitronectin binding assay

A solid phase assay for the study of $\alpha_v\beta_3$ -vitronectin binding was set up

on the basis of already published methods (Wong et al., Molecular Pharmacology 50: 529-537, 1996; Brooks et al., Cell 85: 683-693, 1996). The human $\alpha_v\beta_3$ integrin was diluted into coating buffer (CB) containing 150 mM NaCl, 1 mM CaCl_2 , 1 mM MgCl_2 , 1 mM MnCl_2 , 20 mM TRIS, pH 7.4 at a concentration of 1.5 $\mu\text{g/ml}$. Into 96-well plates, 50 μl of the diluted integrin were added and allowed to bind to the plate walls overnight at 4°C. Next day, the assay plates were emptied and 100 μl of blocking buffer (CB buffer with 3% BSA) were added to each well for 45 min at 37°C. After the incubation, the plates were washed three times with 100 μl assay buffer (AB, CB buffer with 0.1% BSA). Serial 1:1 dilution (25 $\mu\text{l/well}$) of the test compounds were added to the plates, starting from 10 mM solutions in 100% DMSO diluted to 100 μM in AB. The binding reaction was started by addition (25 $\mu\text{l/well}$) of 10 nM biotinylated vitronectin (final concentration: 5 nM), and lasted 30 min at 37°C. The concentration range of the tested compounds spanned from 50 to 0.0005 μM . At the end of the co-incubation, the assay plates were washed as before and 70 μl of a 1:1000 AB dilution of peroxylase-conjugated streptavidin were added per well and were allowed to react for 45 min at 37°C. Then, the plates were washed as described and 50 μl of ready to use Turbo-TMB substrate for peroxylase were added to each well. After 30 minutes incubation at room temperature, the colour development was stopped with 50 μl sulphuric acid 0.38 M and the plates were read at a wavelength of 450 nm with a Packard plate reader. The values obtained were analyzed by four parameters curve fit in the computer program GraphPad Prism, after normalization by a maximum binding control (Bmax) detected in wells where no competitor was added, and a minimum binding control (NSB) detected in wells where no integrin was coated. Under standard assay conditions, A_{450} was never under 1.0 for Bmax, and around 0.15 for NSB. The computerized algorithm gave the concentration of compound needed to inhibit the maximum binding by 50% (IC_{50} value): for those compounds that did not inhibit this binding by 50% at the highest concentration tested, IC_{50} value was reported as being greater then the highest concentration tested. As a positive control, increasing doses of a peptide containing the RGD sequence was added to each plate: IC_{50} value of this

molecule was 120 nM.

Materials

- 5 Human vitronectin receptor ($\alpha_v\beta_3$) was purified from human placenta (Pytela et al., Methods in Enzymology, 144: 475-489, 1987). Turbo-TMB was from PIERCE (34022). BSA (A4503), Vitronectin (V8379), RGD peptide (G4144) and all generic reagents were from SIGMA. Vitronectin was biotinylated according to the procedure indicated in the NHS biotinylation kit
- 10 from PIERCE (21420). Horseradish peroxidase-streptavidin was from Amersham (RPN1231). 96-well plates were from Costar (# 3690, EIA/RIA plate, 1/2 area flat bottom, high binding).

$\alpha_{IIb}\beta_3$ -fibrinogen binding assay

- 15 A solid phase assay for the study of $\alpha_{IIb}\beta_3$ -fibrinogen binding was set up on according to the method described for $\alpha_v\beta_3$. $\alpha_{IIb}\beta_3$ integrin was diluted into coating buffer (CB) containing 150 mM NaCl, 1 mM CaCl_2 , 1 mM MgCl_2 , 1 mM MnCl_2 , 20 mM TRIS, pH 7.4 at a concentration of 3 $\mu\text{g/ml}$. Into 96-well plates,
- 20 50 μl of the diluted integrin were added and allowed to bind to the plate walls overnight at 4°C. Next day, the assay plates were emptied and 100 μl of blocking buffer (CB buffer with 3% BSA) were added to each well for 45 min at 37°C. After the incubation, the plates were washed three times with 100 μl assay buffer (AB, CB buffer with 0.1% BSA); serial 1:1 dilution (25 $\mu\text{l/well}$) of the
- 25 test compounds were added to the plates, starting from 10 mM solutions in 100% DMSO diluted to 100 μM in AB. The binding reaction was started by addition (25 $\mu\text{l/well}$) of 20 nM biotinylated fibrinogen (final concentration: 10 nM), and lasted 30 min at 37°C. The concentration range of the tested compounds spanned from 50 to 0.0005 μM . At the end of the co-incubation, the
- 30 assay plates were washed as before and 70 μl of a 1:1000 AB dilution of peroxidase-conjugated streptavidin were added per well and were allowed to react for 45 min at 37°C. Then, the plates were washed as described and 50 μl

of ready to use Turbo-TMB substrate for peroxidase were added to each well. After 30 minutes incubation at room temperature, the colour development was stopped with 50 μ l sulphuric acid 0.38 M and the plates were read at a wavelength of 450 nm with a Packard plate reader. The values obtained were analysed by four parameters curve fit with the computer program GraphPad Prism, after normalization by a maximum binding control (Bmax) detected in wells where no competitor was added, and a minimum binding control (NSB) detected in wells where no integrin was coated. Under standard assay conditions, A_{450} was never under 0.8 for Bmax, and around 0.15 for NSB. The computerized algorithm gave the concentration of compound needed to inhibit the maximum binding by 50% (IC_{50} value): for those compounds that did not inhibit this binding by 50% at the highest concentration tested, IC_{50} value was reported as being greater than the highest concentration tested. As a positive control, increasing doses of a peptide containing the RGD sequence was added to each plate: IC_{50} value of this molecule was 2.3 μ M for $\alpha_{IIb}\beta_3$ - fibrinogen binding.

Materials

Human fibrinogen receptor ($\alpha_{IIb}\beta_3$) was purified from human platelets ((Pytela et al., Methods in Enzymology, 144: 475-489, 1987). Turbo-TMB was from PIERCE (34022). BSA (A4503), fibrinogen (F4883), RGD peptide (G4144) and all generic reagents were from SIGMA. Fibrinogen was biotinylated according to the procedure indicated in the NHS biotinylation kit from PIERCE (21420). Horseradish peroxidase-streptavidin was from Amersham (RPN1231). 96-well plates were from Costar (# 3690, EIA/RIA plate, 1/2 area flat bottom, high binding).

For example, compound (4-phenyl-6-[[3-(2-pyridinylamino)propanoyl]-amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, **1a**, and compound (4-phenyl-6-[[4-(2-pyridinylamino)butanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, **1b**, when tested in $\alpha_v\beta_3$ -vitronectin and $\alpha_{IIb}\beta_3$ -fibrinogen binding assays, gave the following activity data:

Compound **1a**:

$$\alpha_v\beta_3 \text{ (IC}_{50} \text{ } \mu\text{mol}) = 0.044 \pm 0.025$$

$$\alpha_{IIb}\beta_3 \text{ (IC}_{50} \text{ } \mu\text{mol}) = 30$$

5 Compound **1b**:

$$\alpha_v\beta_3 \text{ (IC}_{50} \text{ } \mu\text{mol}) = 0.024 \pm 0.009$$

$$\alpha_{IIb}\beta_3 \text{ (IC}_{50} \text{ } \mu\text{mol}) = 27$$

10 These test data show that compounds **1a** and **1b** are endowed with high and selective $\alpha_v\beta_3$ inhibiting activity. In fact, the ratio between $\alpha_{IIb}\beta_3$ and $\alpha_v\beta_3$ inhibiting activity is about 1,000.

15 In view of their highly selective $\alpha_v\beta_3$ inhibiting or antagonizing activity, the compounds of the invention can be used in medicine for treating conditions mediated by the $\alpha_v\beta_3$ integrin. Accordingly, the compounds of the invention are useful for instance for treating various conditions or disease states including osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis including tumor angiogenesis, retinopathy including diabetic retinopathy, arthritis including rheumatoid arthritis, psoriasis, periodontal disease, smooth muscle cell
20 migration and restenosis in a mammal in need of such treatment. Additionally, such pharmaceutical agents are useful as antiviral agents, and antimicrobials.

25 According to a preferred object of the invention the $\alpha_v\beta_3$ inhibiting activity results in an anticancer therapy having increased effectiveness in controlling, i.e., slowing, interrupting, arresting, stopping or reversing, the neoplasm formation.

The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion; or topically.

30 The dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the

dosage regime may vary widely. Dosage levels of the order from about 0.01 mg to about 1000 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions and more preferably of the order from about 0.01 mg to about 100 mg/kg of body weight. For instance, the dosage adopted for oral administration to adult humans for compound **1b** may range from about 0.01 mg to about 800 mg/kg of body weight per day and more preferably of the order from about 0.01 mg to about 750 mg/kg body weight.

When given parenterally a suitable daily dose for instance for compound **1b** would typically be about 0.01 to 100 mg/kg body weight injected per day in multiple doses depending on the factors listed above and more preferably from about 0.01 mg to about 10 mg/kg body weight.

The invention includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate, effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, lauryl-sulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example by means of mixing, granulating, tableting, sugar-coating or film-coating processes.

The liquid dispersion for oral administration may be, for instance syrups, emulsions and suspensions.

The syrup may contain as carrier, for example, saccharose or saccharose

with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethyl-cellulose or polyvinyl alcohol.

- 5 The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.

- 10 The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile aqueous, isotonic saline solutions.

The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.


- 15 Compositions for topical application, e.g. creams, lotions or pastes, can be prepared by admixing the active ingredient with a conventional oleaginous or emulsifying excipient.


The following examples describe the invention without limiting it.

20

Example 1


- 25 The preparations of (4-phenyl-6-[[3-(2-pyridinylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, (4-phenyl-6-[[4-(2-pyridinyl-amino)butanoyl]3,4-amino]-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, and of (4-phenyl-6-[[5-(2-pyridinylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid are provided. The synthetic procedures are described in Scheme 1 and Scheme 2.

Scheme 1

Scheme 2

a) NaH, Br(CH₂)₄COOEt, DMF, 75°C (30%); b) 1N NaOH (44%); c) EDCI, DMF, r.t. (62%);
 d) 1N HCl, reflux (68%).


- 5 The synthesis of the ω-[N-carbobenzyloxy-N-(1-oxido-2-pyridinyl)]amino-acids **5** has been carried out as described in Scheme 3.

Scheme 3

a) $\text{H}_2\text{N}(\text{CH}_2)_m\text{COOH}$, *t*-amyl- or isoamyl alcohol, reflux ;

b) $\text{PhCH}_2\text{OCOC(=O)Cl}$, 2N NaOH (33 - 57%, overall);

(4-phenyl-6-{[3-(2-pyridinylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1a



Methyl (6-nitro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 2

10

To a stirred suspension of 4-nitro-2-aminophenol (15.5 g, 100 mmol) and sodium hydrogen carbonate (10 g, 119 mmol) in methanol (100 mL), a solution of methyl-4-bromocrotonate (14 mL, 100 mmol) in methanol (50 mL) was added dropwise during 30 min, then stirring was continued for 4h at room temperature.

15

The reaction mixture was then concentrated *in vacuo* and partitioned between ethyl acetate (250 mL) and water (300 mL). After separation, the aqueous phase was newly extracted with ethyl acetate (2x250 mL). The combined extracts were dried (Na_2SO_4) and evaporated. The resulting oil was dissolved in ethanol (250 mL), potassium carbonate (5 g, 36 mmol) was added and the mixture was stirred for 4h at room temperature. After evaporation, the resulting oil was diluted with dichloromethane (250 mL), washed with water (200 mL), then extracted with 1N hydrochloric acid (150 mL). The aqueous solution was neutralised with 1N sodium hydroxide and extracted with ethyl acetate (3x250

20

mL). Finally, the combined extracts were dried (Na_2SO_4) and evaporated to dryness *in vacuo* to afford the title compound (23 g, 91%) as a red oil.

MS: m/z 294 ($\text{M}+\text{CH}_3\text{CN}+\text{H}^+$), 253 ($\text{M}+\text{H}^+$).

^1H -NMR (300 MHz), δ (CDCl_3): 2.74 (m, 2H), 3.25 (m, 1H), 3.55 (m, 1H), 3.75 (s, 3H), 4.1 (broad signal, 1H), 4.67 (m, 1H), 6.81 (d, 1H), 7.5 (d, 1H), 7.57 (dd, 1H).

Methyl (6-nitro-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 3

To a stirred suspension of **2** (23 g, 91 mmol) in toluene (150 mL), 1,4-cyclohexandione (11 g, 98 mmol) and p-toluenesulfonic acid were added. The resulting solution was stirred and refluxed for 4h, using a condenser equipped with a Dean-Stark apparatus. The reaction mixture was then evaporated. The remaining oil was purified by flash chromatography (*n*-hexane/ethyl acetate 2:1) to afford compound **3** (7.5 g, 25%) as a red-orange oil that solidified on standing.

MS: m/z 329 ($\text{M}+\text{H}^+$).

^1H -NMR (300 MHz), δ (CDCl_3): 2.63-2.89 (m, 2H), 3.55 (m, 1H), 3.71 (s, 3H), 3.82 (m, 1H), 4.78 (m, 1H), 6.9 (d, 1H), 7.22 (m, 3H), 7.43 (m, 2H), 7.63 (dd, 1H), 7.69 (d, 1H).

Methyl (6-amino-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate hydrochloride, 4

Compound **3** (7.5 g, 22.9 mmol) was dissolved in methanol (100 mL). After addition of 10% Pd/C (200 mg) and 37% hydrochloric acid (3 mL), the suspension was shaken in a Parr apparatus under a hydrogen atmosphere (50 psi) for 4h. The reaction mixture was then filtered over Celite, and evaporated to small volume. Upon addition of diethyl ether (150 mL), compound **4** (4.3 g, 56%) precipitated as a light brown solid.

MS: m/z 299 ($\text{M}+\text{H}^+$).

¹H-NMR (300 MHz), δ (DMSO-*d*₆): 2.63-2.86 (m, 2H), 3.5 (m, 1H), 3.61 (s, 3H), 3.78 (m, 1H), 4.57 (m, 1H), 6.6 (dd, 1H), 6.7 (d, 1H), 6.84 (d, 1H), 7.18 (m, 1H), 7.26 (m, 2H), 7.41 (m, 2H), 9.4-9.58 (broad signal, 3H).

5 **N-benzyloxycarbonyl-N-(1-oxido-2-pyridinyl)-beta-alanine, 5 (m = 1)**

2-Chloropyridine N-oxide hydrochloride (5 g, 30.1 mmol), β -alanine (13.36 g, 150 mmol) and sodium hydrogen carbonate (6.15 g, 73 mmol) were suspended in a mixture of isoamyl alcohol (100 mL) and water (7 mL), and
10 refluxed for 48 hours. The reaction mixture was then cooled to room temperature and the solid was filtered off. The solid was washed with methanol (40 mL) and the filtrate was evaporated *in vacuo*. The solid obtained was then shaken in ethanol (100 mL), the insoluble solid filtered off, and the ethanol solution was evaporated *in vacuo*. The solid obtained was suspended in diethyl
15 ether (50 mL), filtered and dried to give the desired crude product, as an extremely hygroscopic material, containing approximately 25% (NMR) of unreacted β -alanine. The crude material, without any further purification, was dissolved in aqueous 2N NaOH (77.5 mL, 155 mmol). The solution was cooled to 0°C then, under vigorous stirring, benzyl chloroformate (13 mL, 92 mmol)
20 was added dropwise. After 4 hours at 0°C, the reaction mixture was allowed to warm to room temperature then stirred overnight. The reaction mixture was then washed with Ethyl acetate (2x30 mL), acidified to pH 2 and extracted with Ethyl acetate (5x50 mL). The organic phase was dried over sodium sulfate and evaporated *in vacuo*. The residue was purified by flash chromatography
25 (CH₂Cl₂/MeOH/AcOH: 95/5/0.5) to give 5 (m = 1), as a light yellow oil (5.4 g, 57% overall).

MS: m/z 317 (M+H⁺).

¹H-NMR (300 MHz), δ (DMSO-*d*₆): 2.5 (t, 2H, partially overlapped with DMSO), 3.7-3.82 (broad signal, 2H), 5.05 (s, 2H), 7.1-7.4 (m, 7H), 7.5 (m, 1H), 8.34 (m,
30 1H).

Methyl [6-({3-[N-benzyloxycarbonyl-N-(1-oxido-2-pyridinyl)amino]-propanoyl} amino)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, **6 (m = 1)**

5 To a stirred solution of N-(benzyloxycarbonyl)-N-(1-oxido-2-pyridinyl)-beta-alanine **5** (0.79 g, 2.5 mmol) in anhydrous DMF (15 mL) cooled to 0°C, compound **4** (0.9 g, 2.7 mmol), 4-dimethylaminopyridine (0.4 g, 3.3 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.6 g, 3.13 mmol) were added. After stirring for 1h at 0°C, the solution was allowed to stand
10 overnight at room temperature. Water (100 mL) was then added and the suspension was extracted with ethyl acetate (3x100 mL). The combined extract were dried (Na₂SO₄), evaporated and the resulting crude was purified by flash chromatography (ethyl acetate/methanol 9:1) to afford **6** (1.13 g, 76%).

MS: m/z 597 (M+H⁺).

15 ¹H-NMR (300 MHz), δ (CDCl₃): 2.5 (t, 2H), 2.56-2.83 (m, 2H), 3.48 (m, 1H), 3.7 (s, 3H), 3.75 (m, 1H), 3.98 (broad signal, 2H), 4.61 (m, 1H), 5.02 (broad s, 2H), 6.8 (m, 2H), 7.03-7.4 (m, 13H), 8.01 (broad s, 1H), 8.13 (d, 1H), 9 (broad s, 1H).

Methyl [6-({3-[N-(benzyloxycarbonyl)-N-(2-pyridinyl)amino]propanoyl} amino)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, **7 (m = 1)**

To a stirred solution of stannous chloride (0.44 g, 2.3 mmol) in anhydrous THF, under argon, a 1M dichloromethane solution of titanium(IV) chloride (2.3 ml, 2.3 mmol) was added dropwise at room temperature. After addition was
25 completed, the reaction mixture was stirred 1h at room temperature. A dichloromethane solution (15 mL) of **6** (1.12 g, 1.88 mmol) was added dropwise and stirring continued for 2h. The reaction mixture was quenched with water (100 mL), neutralised with 2N sodium hydroxide and the resulting solution was extracted with ethyl acetate (3x100 mL). The combined extracts were dried
30 (Na₂SO₄), evaporated to dryness and the resulting compound **7** (1 g, 99%) was then submitted to the next step without further purification.

MS: m/z 581 (M+H⁺).


Methyl (4-phenyl-6-[[3-(2-pyridinylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 8 (m = 1)

To a stirred solution of **7** (1 g, 1.72 mmol) in THF/water 5:1 (25 ml), 10%
5 Pd/C (100 mg) and ammonium formate (1 g, 15.86 mmol) were added at room temperature. Stirring was continued for 2h, then the solution was filtered over Celite, diluted with ethyl acetate (100 mL), washed with brine, dried (Na₂SO₄), and evaporated to dryness. The resulting product was purified by flash chromatography on silica gel (ethyl acetate/*n*-hexane 4:1) to give the title
10 compound (610 mg, 79.5%).
MS: *m/z* 447 (M+H⁺).

(4-phenyl-6-[[3-(2-pyridinylamino)propanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1a

15 To an ethanol (10 mL) solution of **8** (0.61 g, 1.37 mmol) 1N NaOH (3 mL) was added and the resulting solution was stirred for 1h at room temperature. After neutralization with 1N hydrochloric acid, the mixture was extracted with ethyl acetate (3x50 mL) and dried. Partial evaporation of the solvent afforded a
20 white precipitate that was collected to give **1a** (0.2 g, 35%).
¹H-NMR (400 MHz), δ (DMSO-*d*₆): 2.44 (t, 2H, J=7.4, CH₂CONH), 2.60 (m, 2H, CH₂COOH), 4.41 (m, 1H, OCH), 6.41 (m, 3H, H3' + H5' + NH), 6.69 (d, 1H, J=8.6, H-8 benzoxazine), 6.97 (dd, 1H, J=8.6, 2.3, H-7 benzoxazine), 7.09 (m, 1H), 7.20 (d, 1H, J=2.3, H-5 benzoxazine), 7.20-7.40 (m, 5H, aromatic
25 hydrogens), 7.91 (m, 1H, H-6 pyridine); 9.57 (s, 1H, NHCO).

(4-phenyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1b



4-[N-(benzyloxycarbonyl)-N-(1-oxido-2-pyridinyl)amino]butanoic acid, 5
(m = 2)

5 2-Chloropyridine *N*-oxide hydrochloride (15 g, 90.3 mmol), 4-amino-
butanoic acid (46 g, 446 mmol) and sodium hydrogen carbonate (18.4 g, 219
mmol) were suspended in a mixture of *tert*-amyl alcohol (300 mL) and water (20
mL), and refluxed for 50 hours. The reaction mixture was then cooled at room
temperature and the solid was filtered off. The solid was washed with methanol
10 (70 mL) and the filtrate was evaporated *in vacuo*. The crude solid obtained was
shaken in ethanol (300 mL), the insoluble solid was filtered off, and the ethanol
solution was evaporated *in vacuo*. The solid obtained was suspended in diethyl
ether (150 mL), filtered and dried to give N-(1-oxido-2-pyridinyl)amino]butanoic
acid as a light yellow solid (15.7 g, 88.5%).

15 MS: m/z 197 (M+H⁺).

¹H-NMR (300 MHz), δ (DMSO-*d*₆): 1.75 (m, 2H), 2.2 (t, 2H), 3.22 (q, 2H), 6.56
(dt, 1H), 6.8 (dd, 1H), 7.19 (m, 2H), 8.05 (dd, 1H).

4-[(1-oxido-2-pyridinyl)amino]butanoic acid (5 g, 25.5 mmol) was dissolved in
20 aqueous 2N NaOH (100 mL, 200 mmol). The solution was cooled to 0°C then,
under vigorous stirring, benzyl chloroformate (17.6 mL, 124.8 mmol) was added
dropwise. After 4 hours at 0°C, the reaction mixture was warmed at room
temperature then stirred overnight. The reaction mixture was then washed with
Ethyl acetate (2x50 mL), acidified until pH 2 and extracted with Ethyl acetate
25 (5x50 mL). The organic phase was dried over sodium sulfate and evaporated *in*
vacuo to give the crude product that was suspended in 30 mL of Ethyl acetate,
filtered, washed with diethyl ether and dried to give the title compound (3.12 g,
37%).

MS: m/z 331 (M+H⁺).

30 ¹H-NMR (300 MHz), δ (DMSO-*d*₆): 1.62 (m, 2H), 2.25 (t, 2H), 3.5-3.67 (broad s,
2H), 5.05 (s, 2H), 7.2-7.4 (m, 7H), 7.56 (m, 1H), 8.3 (m, 1H).

Methyl [6-({4-[N-(benzyloxycarbonyl)-N-(1-oxido-2-pyridinyl)amino]butanoyl} amino)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, 6 (m = 2)

5 To a stirred solution of 4-[N-(benzyloxycarbonyl)-N-(1-oxido-2-pyridinyl)-amino]butanoic acid **5** (m = 2, 0.6 g, 1.82 mmol) in anhydrous DMF (15 mL), cooled to 0°C, compound **4** (0.9 g, 2.7 mmol), 4-dimethylaminopyridine (0.4 g, 3.3 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.6 g, 3.13 mmol) were added. After stirring for 1h at 0°C, the solution was
10 allowed to stand overnight at room temperature. Water (100 mL) was then added and the suspension was extracted with ethyl acetate (3x100 mL). The combined extract were dried (Na₂SO₄), evaporated and the resulting crude product was purified by flash chromatography on silica gel (ethyl acetate/methanol 9:1) to afford **6** (m = 2, 1.05 g, 94.5%).

15 MS: m/z 611 (M+H⁺).

¹H-NMR (300 MHz), δ (CDCl₃): 1.61 (broad s, 2H), 2.42 (broad t, 2H), 2.55-2.85 (m, 2H), 3.46 (m, 1H), 3.7 (s, 3H), 3.75 (m, 3H), 4.62 (m, 1H), 5.1 (s, 2H), 6.78 (m, 1H), 7.01-7.41 (m, 14H), 8.01 (dd, 1H), 8.31 (broad s, 1H).

20 **Methyl [6-({4-[N-(benzyloxycarbonyl)-N-(2-pyridinyl)amino]butanoyl}-amino)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, 7 (m = 2)**

To a stirred solution of stannous chloride (0.38 g, 2 mmol) in anhydrous THF, under argon, a 1M dichloromethane solution of titanium(IV) chloride (2
25 mL) was added dropwise at room temperature. Once the addition was completed, the reaction mixture was stirred for 1h at room temperature then a dichloromethane solution (15 mL) of **6** (m = 2, 1 g, 1.64 mmol) was added dropwise and stirring continued for 2 additional hours. The reaction mixture was then quenched with water (100 mL), neutralised with 2N NaOH and extracted
30 with ethyl acetate (3x100 mL). The combined extracts were dried (Na₂SO₄), evaporated and the crude product (0.97 g, quantitative yield) was then submitted to the next step without further purification.

MS: m/z 595 (M+H⁺).


Methyl (4-phenyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 8 (m = 2)

- To a stirred solution of **7** (m = 2, 0.95 g, 1.6 mmol) in THF/water 5:1 (25 mL), 10% Pd/C (0.1 g) and ammonium formate (1 g) were added. Stirring was continued for 2h, then the solution was filtered over Celite and diluted with ethyl acetate (100 mL), washed with brine, dried (Na₂SO₄), evaporated and the resulting product was purified by flash chromatography (ethyl acetate/*n*-hexane 4:1) to give **8** (m = 2, 0.54 g, 73%).
- MS: m/z 461 (M+H⁺).

(4-phenyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1b

- To an ethanol (10 mL) solution of **8** (m = 2, 0.54 g, 1.17 mmol), 1N NaOH (3 mL) was added and the resulting solution was stirred for 1h at room temperature. After neutralization with 1N HCl, the mixture was extracted with ethyl acetate (3x50 mL) and dried. The solution was partially evaporated. Collection of the precipitate afforded the title compound (0.185 g, 37%).
- ¹H-NMR (400 MHz), δ (DMSO-*d*₆): 1.75 (m, 2H, CH₂CH₂CH₂), 2.21 (t, 2H, J=7.4, CH₂CH₂CH₂CO), 2.60 (m, 2H, CH₂COOH), 4.42 (m, 1H, OCH), 6.40 (m, 3H, NH + H-3 and H-5 pyridine), 6.69 (d, 1H, J=8.6, H-8 benzoxazine), 6.97 (dd, 1H, J=8.6, 2.3, H-7 benzoxazine), 7.08 (m, 1H), 7.14 (d, 1H, J=2.3, H-5 benzoxazine), 7.20-7.40 (m, 5H, aromatic hydrogens), 7.89 (m, 1H, H-6 pyridine), 9.55 (s, 1H, NHCO).

4-phenyl-6-[[5-(2-pyridinylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1c



The compound has been synthesized as reported in Scheme 2.

Ethyl 5-[N-formyl-N-(2-pyridinyl)amino]pentanoate, 9

5 To a stirred suspension of 60% sodium hydride in mineral oil (2 g, 50 mmol) in DMF (160 mL), cooled to 0°C, 2-aminopyridine (3.94 g, 41.9 mmol), previously dissolved in DMF (20 mL), was added. After 15 minutes at 0°C, the suspension was warmed to room temperature, stirred for an additional hour, then ethyl 5-bromovalerate (8.4 mL, 209 mmol) was added. The reaction
10 mixture was then heated at 75°C overnight, cooled, concentrated *in vacuo* and poured into Ethyl acetate (100 mL). The organic phase was washed with water (50 mL), NaHCO₃ aqueous saturated solution (50 mL) and brine (50 mL), dried and concentrated to afford a deep brown oil (6g) that was purified by flash chromatography (ethyl acetate/*n*-hexane: 1:1 then 7:3) to give **9** as a yellow oil
15 (3.1 g, 30%).

MS: *m/z* 251 (M+H⁺).

¹H-NMR (300 MHz), δ (CDCl₃): 1.21 (t, 3H), 1.65 (m, 4H), 2.3 (m, 2H), 3.93 (m, 2H), 4.07 (q, 2H), 7.02 (d, 1H), 7.1 (m, 1H), 7.7 (dt, 1H), 8.4 (dd, 1H), 9.18 (s, 1H).

20

5-[N-formyl-N-(2-pyridinyl)amino]pentanoic acid, 10

To a stirred solution of **9** (3.1 g, 12.4 mmol) in ethanol (120 mL), 1N NaOH (31 mL, 31 mmol) was added. After 3 hours at room temperature, the reaction
25 mixture was quenched with 1N HCl until pH 7, then concentrated *in vacuo*. The residue was suspended in dichloromethane, filtered and the filtrate was newly evaporated. The crude product was purified by flash chromatography (ethyl acetate/*n*-hexane: 9/1) to afford the desired product **10** as a light yellow oil (1.2 g, 44%).

30 MS: *m/z* 223 (M+H⁺).

¹H-NMR (300 MHz), δ (CDCl₃): 1.67 (m, 4H), 2.37 (m, 2H), 3.98 (m, 2H), 7.03 (d, 1H), 7.11 (m, 1H), 7.7 (dt, 1H), 8.4 (dd, 1H), 9.18 (s, 1H).

Methyl [6-({5-[N-formyl-N-(2-pyridinyl)amino]pentanoyl}amino)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, 11

To a stirred solution of **10** (0.6 g, 2.7 mmol) in anhydrous DMF (15 mL),
5 cooled at 0°C, compound **4** (0.9 g, 2.7 mmol), 4-dimethylaminopyridine (0.4 g, 3.3 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.6 g, 3.13 mmol) were added. After stirring for 1h at 0°C, the solution was allowed to stand overnight at room temperature. Water (100 mL) was then added and the suspension obtained was extracted with ethyl acetate (3x100
10 mL). The combined extract were dried (Na₂SO₄), evaporated and the resulting crude product was purified by flash chromatography on silica gel (ethyl acetate/*n*-hexane 2:1) to afford compound **11** (0.835 g, 62%).

MS: *m/z* 503 (M+H⁺).

¹H-NMR (300 MHz), δ (CDCl₃): 1.67 (m, 4H), 2.31 (broad t, 2H), 2.56-2.85 (m,
15 2H), 3.48 (m, 1H), 3.7 (s, 3H), 3.76 (m, 1H), 3.98 (broad t, 2H), 4.63 (m, 1H), 6.8 (d, 1H), 6.92 (dd, 1H), 7-7.4 (m, 8H), 7.7 (broad t, 1H), 8.37 (dd, 1H), 9.13 (broad s, 1H).

4-phenyl-6-[[5-(2-pyridinylamino)pentanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid, 1c

20

A suspension of **11** (0.83 g, 1.65 mmol) in 1N hydrochloric acid (5 mL),
was heated at reflux for 1h. The reaction mixture was then neutralised with 1N NaOH, extracted with ethyl acetate (3x50 mL) and dried. The solution was
25 partially evaporated. Filtration of the precipitate formed afforded compound **1c** (0.5 g, 68%).

¹H-NMR (400 MHz), δ (DMSO-*d*₆): 1.54 (m, 4H, CH₂CH₂CH₂CH₂), 2.18 (t, 2H, J=7.1, CH₂CH₂CH₂CH₂CO), 2.57 (m, 2H, CH₂COOH), 3.40 (m, 4H), 3.76 (m, 1H, PhNCH₂), 4.42 (m, 1H, OCH₂), 6.69 (d, 1H, J=8.7, H-8 benzoxazine), 6.97
30 (dd, 1H, J=2.3, 8.8, H-7 benzoxazine), 7.07 (m, 1H), 7.14 (d, 1H, J=2.3, H-5 benzoxazine), 7.20 (m, 2H), 7.34 (m, 1H, H-4 pyridine), 7.37 (m, 2H), 7.90 (m, 1H, H-6 pyridine), 9.51 (s, 1H, NHCO).


By analogous procedures the following compounds can be obtained:

- (4-phenyl-6-{[3-(1H-imidazol-2-ylamino)propanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 5 (4-phenyl-6-{[4-(1H-imidazol-2-ylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-phenyl-6-{[5-(1H-imidazol-2-ylamino)pentanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

10 **Example 2**


The preparation of (4-benzyl-6-{[4-(2-pyridinylamino)butanoyl]amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid is described. The synthesis has been performed as described in Scheme 4.

15

Scheme 4

- a) Na_2CO_3 , BrCH_2Ph , DMF, 90°C (66%);
 b) Zn dust, AcOH/MeOH (90%);
 c) EDCI, DMAP, DMF, r.t. (70%);
 d) 1N HCl, reflux (60%).

(4-benzyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1d



5 Methyl (4-benzyl-6-nitro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 12

To a stirred suspension of methyl (6-nitro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate **2** (2.52 g, 10 mmol) and anhydrous sodium carbonate (2 g.) in anhydrous DMF (15 mL), benzyl bromide (1.5 mL, 12.6 mmol) was added.

10 The resulting suspension was stirred 2 hours at 90°C. The reaction mixture was then diluted with ethyl acetate (100 mL) and washed with water (3 x 100 mL). After separation, the organic phase was dried (Na₂SO₄) and evaporated to dryness *in vacuo* to afford the title compound (2.25g, 66%) as a yellow-orange oil.

15 MS: m/z 343 (M+H)⁺, 685 (2M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 2.6-2.7 (m, 2H), 3.2 (m, 1H), 3.42 (m, 1H), 3.7 (s, 3H), 4.5 (m, 2H), 4.7 (m, 1H), 6.85 (d, 1H), 7.3 (m, 5H), 7.4 (m, 2H)

Methyl (6-amino-4-benzyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 13

20

To a stirred solution of methyl (4-benzyl-6-nitro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate **12** (1.25g, 3.7 mmol) in acetic acid (15 mL) and methanol (0.5 mL) at 0°C, zinc dust (1g) was added. The suspension was stirred for 1 hour. After filtering under a pad of celite the solution was evaporated

25 to dryness *in vacuo*. The residue was taken up with ethyl acetate (100 mL) and washed with saturated sodium hydrogen carbonate (100mL), brine (2 x 100 mL) and then dried (Na₂SO₄) and evaporated to dryness *in vacuo* to afford the title compound (1g, 90%) as a brown oil.

MS: m/z 313 (M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 2.6 (m, 2H), 3 (m, 1H), 3.2 (m, 1H), 3.7 (s, 3H), 4.25 (m, 2H), 4.5 (m, 1H), 6.4 (d, 1H), 6.6 (m, 5H), 6.7 (m, 2H)

5 **Methyl [4-benzyl-6-({4-[N-formyl-N-(2-pyridinyl)amino]butanoyl}amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, 14**

To a stirred solution of 4-[formyl(2-pyridinyl)amino]butanoic acid **10** (265 mg, 1.27 mmol) in anhydrous DMF (15 mL) cooled at 0°C, methyl (6-amino-4-benzyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate **13** (410 mg, 1.3 mmol),
10 DMAP (250 mg.) and EDCI-HCl (300 mg, 1.6 mmol) were added. After stirring 1 hour at 0°C, the solution was allowed to stand overnight at room temperature. Water (100 mL) was then added and the suspension was extracted with ethyl acetate (3 x 100 mL). The combined extract were dried (Na₂SO₄), evaporated and the resulting crude was purified by flash chromatography on silica gel (ethyl
15 acetate/n-hexane 4:1) to afford **14** (460 mg, 70%).

MS: m/z 503 (M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 1.9 (broad triplet, 2H), 2.2 (broad triplet, 2H), 2.65-2.9 (m, 2H), 3.6 (s, 3H), 3.7 (m, 1H), 3.75 (m, 1H), 3.9 (broad triplet, 2H), 4.2 (m, 2H), 4.6 (m, 1H), 6.65 (dd, 1H), 6.85-7.7 (m, 10H), 8.3 (dd, 1H), 8.4
20 (broad singlet, 1H), 9.3 (broad singlet, 1H).

(4-benzyl-6-{{4-(2-pyridinylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1d

25 A solution of methyl [4-benzyl-6-({4-[formyl(2-pyridinyl)amino]butanoyl}amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate **14** (450 mg, 0.89 mmol) in 1N hydrochloric acid (5 mL) was refluxed for 1 hour. The resulting solution was cooled and after neutralization with 1N sodium hydroxide a white precipitate was obtained, which after washing and drying gave **1d** (250 mg, 60%).

30 MS: m/z 461 (M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 1.9 (broad triplet, 2H), 2.2 (broad triplet, 2H), 3.2 (m, 2H), 3.7 (m, 1H), 3.75 (m, 1H), 3.9 (broad triplet, 2H), 4.2 (m, 2H), 4.4 (m,

1H), 6.4 (m, 3H), 6.80 (d, 1H), 7.3 (m, 2H) 7.5 (m, 5H) 7.7 (broad singlet, 1H) 7.9 (m, 1H), 8.4 (broad singlet, 1H), 9.7 (broad singlet, 1H).

By analogous procedures, the following compounds can be obtained:

5

(4-benzyl-6-[[3-(2-pyridinylamino)propanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[[5-(2-pyridinylamino)pentanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

10 (4-benzyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-benzyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

15 (4-methyl-6-[[3-(2-pyridinylamino)propanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-[[4-(2-pyridinylamino)butanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

20 (4-methyl-6-[[5-(2-pyridinylamino)pentanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-[[3-(1H-imidazol-2-ylamino)propanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-methyl-6-[[4-(1H-imidazol-2-ylamino)butanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

25 (4-methyl-6-[[5-(1H-imidazol-2-ylamino)pentanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-[[3-(2-pyridinylamino)propanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

30 (4-cyclopropylmethyl-6-[[4-(2-pyridinylamino)butanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-[[5-(2-pyridinylamino)pentanoyl] amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclopropylmethyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

5 (4-cyclopropylmethyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{{3-(2-pyridinylamino)propanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

10 (4-cyclohexylmethyl-6-{{4-(2-pyridinylamino)butanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{{5-(2-pyridinylamino)pentanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;


15 (4-cyclohexylmethyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

(4-cyclohexylmethyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid.

20 **Example 3**


The preparation of (4-benzoyl-6-{{4-(2-pyridinylamino)butanoyl} amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid is described. The synthesis has been performed as described in Scheme 5.

25

Scheme 5

- a) Na_2CO_3 , PhCOCl, DMF, r.t.(93%);
b) Zn dust, AcOH/MeOH (90%);
c) EDCI, DMAP, DMF, r.t. (60%);
d) 1N HCl, reflux (20%).

(4-benzoyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1e



5 Methyl (4-benzoyl-6-nitro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 15

To a stirred suspension of methyl (6-nitro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate **2** (2.52 g, 10 mmol) and anhydrous sodium carbonate (2 g.) in anhydrous DMF (15 mL) and anhydrous pyridine (5 mL), benzoyl chloride
 10 (1.5 mL, 12.96 mmol) was added. The resulting suspension was stirred 8 hours at room temperature. The reaction mixture was then diluted with ethyl acetate (100 mL) and washed with water (3 x 100 mL). After separation the organic phase was dried (Na₂SO₄) and evaporated to dryness *in vacuo* to afford the title compound (3.3g, 93%) as a yellow-orange oil.

15 MS: m/z 357 (M+H)⁺, 374 (M+NH₄)⁺
¹H-NMR (300 MHz), δ (CDCl₃): 2.58-2.64 (m, 2H), 3.30 (m, 1H), 3.64 (m, 1H), 3.7 (s, 3H), 5.10 (m, 1H), 6.88 (d, 1H), 7.3 (m, 5H), 7.7 (m, 2H)

Methyl (4-benzoyl-6-amino-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 16

20

To a stirred solution of **15** (1.65g, 4.6 mmol) in acetic acid (15 mL) and methanol (0.5 mL) at 0°C, zinc dust (2 g) was added. The suspension was stirred for 1 hour. After filtering under a pad of celite the solution was evaporated to dryness *in vacuo*. The residue was taken up with ethyl acetate
 25 (100 mL) and washed with saturated sodium hydrogen carbonate (100 mL), brine (2 x 100 mL) and then dried (Na₂SO₄) and evaporated to dryness *in vacuo* to afford the title compound (1.3 g, 90%) as a brown oil.

MS: m/z 327 (M+H)⁺, 653 (2M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 2.4-2.5 (m, 2H), 3-3.5 (m, 2H), 3.6 (s, 3H), 4.3 (m, 1H), 6.5 (m, 2H), 7.2-7.6 (m, 6H).

Methyl [4-benzoyl-6-({4-[N-formyl-N-(2-pyridinyl)amino]butanoyl}amino)-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, 17

5

To a stirred solution of 4-[formyl(2-pyridinyl)amino]butanoic acid **10** (265 mg, 1.27 mmol) in anhydrous DMF (15 mL) cooled at 0°C, methyl (6-amino-4-benzoyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate **16** (430 mg, 1.3 mmol), DMAP (250 mg) and EDCI-HCl (300 mg, 1.6 mmol) were added. After stirring 1 hour at 0°C, the solution was allowed to stand overnight at room temperature. Water (100 mL) was then added and the suspension was extracted with ethyl acetate (3 x 100 mL). The combined extract were dried (Na₂SO₄), evaporated and the resulting crude was purified by flash chromatography on silica gel (ethyl acetate/n-hexane 5:1) to afford compound **17** (420 mg, 60%).

15 MS: m/z 517 (M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 1.95 (broad triplet, 2H), 2.3 (broad triplet, 2H), 2.58-2.85 (m, 2H), 3.6 (m, 1H), 3.7 (s, 3H), 3.75 (m, 1H), 3.98 (broad triplet, 2H), 4.75 (m, 1H), 6.85 (d, 1H), 7.15-7.75 (m, 10H), 8.4 (dd, 1H), 8.1 (broad singlet 1H), 9.15 (broad singlet, 1H).

20

(4-benzoyl-6-{{4-(2-pyridinylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid, 1e

A solution of **17** (280 mg, 0.54 mmol) in 1N hydrochloric acid (5 mL) was refluxed for 1 hour. The resulting solution was cooled and after neutralization with 1N sodium hydroxide a white precipitate was obtained, which after washing and drying gave compound **1e** (50 mg, 20%).

MS: m/z 475 (M+H)⁺


30 By analogous procedures the following compounds can be obtained:

(4-benzoyl-6-{{3-(2-pyridinylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

- (4-benzoyl-6-{{5-(2-pyridinylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 5 (4-benzoyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-benzoyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{3-(2-pyridinylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 10 (4-nicotinoyl-6-{{4-(2-pyridinylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{5-(2-pyridinylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 15 (4-nicotinoyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{4-(1H-imidazol-2-ylamino)butanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- (4-nicotinoyl-6-{{5-(1H-imidazol-2-ylamino)pentanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;
- 20 (4-nicotinoyl-6-{{3-(1H-imidazol-2-ylamino)propanoyl}amino}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid;

Example 4

- The preparation of (4-phenyl-6-{{3-(2-pyridinylamino)propylamino}-carbonyl}-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid is described. The
- 25 synthesis has been performed as described in Scheme 6.

Scheme 6

- a) *t*-butanol, H_2SO_4 , MgSO_4 , r.t. (90%);
 b) H_2 , Pd/C, MeOH (95%);
 c) methyl 4-bromo-2-butenate, NaHCO_3 , r.t. (91%);
 d) 1,4-cyclohexandione, PTSA, toluene, reflux (52%);
 e) EDCI, DMF, r.t. (20%);
 f) 1N NaOH, EtOH, r.t. (43%).

***tert*-butyl 4-hydroxy-3-nitrobenzoate**

Magnesium sulfate anhydrous (9.62 g, 80 mmol) was suspended at room temperature in dichloromethane (50 mL) and 96% sulfuric acid (1.1 mL, 20 mmol) was added, the mixture was vigorously stirred for 15 min and then 4-hydroxy-3-nitrobenzoic acid (3.7 g, 20.22 mmol) and *tert*-butanol (9.6 mL, 100 mmol) were added. Stirring was continued for 48 hours. A saturated sodium hydrogen carbonate solution (150 mL) was slowly added and the mixture was diluted with dichloromethane (150 mL). The organic layer was separated and dried (Na₂SO₄), evaporated to afford *tert*-butyl 4-hydroxy-3-nitrobenzoate as a yellow solid (4.43 g, 90%).

MS: *m/z* 238 (M-H)⁻

¹H-NMR (300 MHz), δ (CDCl₃): 1.7 (s, 9H), 7.2 (d, 1H), 8.2 (d, 1H), 8.75 (s, 1H), 10.8 (broad singlet, 1H).

***tert*-butyl 4-hydroxy-3-aminobenzoate**

To a solution of *tert*-butyl 4-hydroxy-3-nitrobenzoate (4.4 g, 18.4 mmol) in methanol (50 mL), 10% Pd/C (200 mg) was added and the resulting suspension was hydrogenated at 50 psi for 4 hours. After filtering under a pad of celite, methanol was removed *in vacuo* to obtain the title compound as a greenish powder (3.5 g, 95%).

MS: *m/z* 210 (M+H)⁺, 419 (2M+H)⁺, 208 (M-H)⁻

¹H-NMR (300 MHz), δ (CDCl₃): 1.7 (s, 9H), 4.2 (broad singlet, 2H) 6.75 (d, 1H), 7.6 (m, 2H).

Methyl (6-*tert*-butoxycarbonyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetate, 18

To a stirred solution of *tert*-butyl 4-hydroxy-3-aminobenzoate (3 g, 14.35 mmol) in methanol (20 mL) sodium hydrogen carbonate (1.5 g) was added and a solution of methyl-4-bromo crotonate (3 mL, 17 mmol) in methanol (5 mL) was added dropwise in 30 minutes and the resulting suspension was stirred 4h at

room temperature. The reaction mixture was concentrated *in vacuo* and taken up with ethyl acetate (250 mL) and water (300 mL). The organic phase was separated and the aqueous phase was extracted with more ethyl acetate (2 x 250 mL). The combined extracts were dried (Na_2SO_4) evaporated and the resulting oil dissolved in ethanol (25 mL), potassium carbonate (1 g) was added and the resulting suspension was stirred 4 h at room temperature. The reaction mixture was evaporated *in vacuo* and the resulting oil was diluted with dichloromethane (150 mL) and washed with water (3 x 100 mL), the organic solution was then extracted with hydrochloric acid 1N (150 mL) and separated, the aqueous solution was neutralized with 1N sodium hydroxide and extracted with ethyl acetate (3 x 150 mL). The combined extract were dried (Na_2SO_4) evaporated to dryness *in vacuo*, the resulting crude was purified by flash chromatography on silica gel (n-hexane/ethyl acetate 3:1) to afford *tert*-butyl 2-(2-methoxy-2-oxoethyl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate (5.4 g) as a white solid.

MS: m/z 308 ($\text{M}+\text{H}$)⁺, 615 ($2\text{M}+\text{H}$)⁺, 306 ($\text{M}-\text{H}$)⁻, 366 ($\text{M} + \text{AcOH} - \text{H}$)⁻.

¹H-NMR (300 MHz), δ (CDCl_3): 1.55 (s, 9H), 2.6 (m, 1H), 2.8 (m, 1H), 3.2 (m, 1H), 3.45 (m, 1H), 3.75 (s, 3H), 4.65 (m, 1H), 6.8 (dd, 1H), 7.25 (dd, 1H), 7.35 (dd, 1H).

2-(2-methoxy-2-oxoethyl)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid, 19

To a stirred suspension of *tert*-butyl 2-(2-methoxy-2-oxoethyl)-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate (5.3 g, 17.3 mmol) in toluene (50 mL) 1,4-cyclohexandione (2.8 g, 25 mmol) and *p*-toluenesulfonic acid (1 g) were added. The resulting solution was stirred at reflux for 4 hours, using a condenser equipped with a Dean-Stark apparatus. The reaction mixture was concentrated *in vacuo*. The remaining oil was purified by flash chromatography on silica gel column eluting with ethyl acetate to give 2-(2-methoxy-2-oxoethyl)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid (2.9 g, 52%) as a white solid.

MS: m/z 328 ($\text{M}+\text{H}$)⁺, 655 ($2\text{M}+\text{H}$)⁺, 306 ($\text{M}-\text{H}$)⁻

¹H-NMR (300 MHz), δ (CDCl₃): 2.65 (m, 1H), 2.85 (m, 1H), 3.55 (m, 1H), 3.7 (s, 3H), 3.85 (m, 1H), 4.75 (m, 1H), 6.9 (d, 1H), 7.15-7.4 (m, 5H), 7.45 (dd, 1H), 7.6 (d, 1H).

5 N-(2-pyridinyl)-1,3-propanediamine

A mixture of 2-bromopyridine (12.3 mL, 126.7 mmol) and pyridine (13 mL, 161 mmol) in 1,3-diaminopropane (53.5 mL, 640 mmol) was refluxed under nitrogen for 18 hours. The reaction mixture was evaporated under reduced pressure and cooled, and the resulting residue was treated with THF (150 mL) to yield a white precipitate. The precipitate was filtered and washed with additional THF (100 mL). Evaporation of the filtrate afforded an orange oil, which was distilled *in vacuo* to give N-(2-pyridinyl)-1,3-propanediamine (9.6 g, 50%) as a colorless oil : bp 128 – 132 °C (2 mmHg).

MS: m/z 152 (M+H)⁺

¹H-NMR (300 MHz), δ (CDCl₃): 1.28 (broad singlet, 2H), 1.75 (m, 2H), 2.84 (t, 2H), 3.35 (m, 2H) 5.00 (broad singlet, 1H) 6.50 (m, 2H) 7.40 (dd, 1H), 8.07 (1H,

20 Methyl [4-phenyl-6-[[3-(2-pyridinylamino)propylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetate, 20

To a stirred solution of 2-(2-methoxy-2-oxoethyl)-4-phenyl-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylic acid (330 mg, 1 mmol) in anhydrous DMF (15 mL) cooled at 0°C, N-(2-pyridinyl)-1,3-propanediamine (200 mg, 1.3 mmol), DMAP (150 mg) and EDCI-HCl (300 mg, 1.6 mmol) were added. After stirring 1 hour at 0°C, the solution was allowed to stand overnight at room temperature. Water (100 mL) was then added and the suspension was extracted with ethyl acetate (3 x 100 mL). The combined extract were dried (Na₂SO₄), evaporated and the resulting crude was purified by flash chromatography on silica gel (ethyl acetate/n-hexane 4:1) to afford the title compound (100 mg, 20%) as a white solid.

MS: m/z 461 (M+H)⁺

[4-phenyl-6-[[3-(2-pyridinylamino)propylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid, 1f

To a stirred solution of compound 20 (80 mg, 0.17 mmol) in ethanol (10 mL) were added 0.18 mL of 1N NaOH solution. The reaction mixture is stirred at room temperature for 3 hours and left standing overnight. After neutralization with 2N HCl (0.08 mL), absolute ethanol is added (10 mL) is added, the solution is evaporated *in vacuo* and the residue is purified by filtration through a small pad of silica gel, eluting with dichloromethane and methanol (8:2) to give 33 mg (43%) of the title compound.

MS: : m/z 447 (M+H)⁺

According to the same procedure, the following compounds can be prepared:

[4-phenyl-6-[[2-(2-pyridinylamino)ethylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[[4-(2-pyridinylamino)butylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[[2-(1H-imidazol-2-ylamino)ethylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[[3-(1H-imidazol-2-ylamino)propylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid;

[4-phenyl-6-[[4-(1H-imidazol-2-ylamino)butylamino]carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid.

Example 5

Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.

Composition for 500 capsules:

(4-phenyl-6-[[4-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl]acetic acid

10 g

Lactose	80 g
Corn starch	5 g
Magnesium stearate	5 g

- This formulation is encapsulated in two-piece hard gelatin capsules and
5 dosed at 0.200 g for each capsule.

Example 6

- Tablets, each weighing 0.150 g and containing 25 mg of the active
10 substance, can be manufactured as follows.

Composition for 10,000 tablets:

- | | |
|---|-------|
| (4-phenyl-6-[[3-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benz-oxazin-2-yl)acetic acid | 250 g |
| Lactose | 800 g |
| 15 Corn starch | 415 g |
| Talc powder | 30 g |
| Magnesium stearate | 5 g |

- The (4-phenyl-6-[[3-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-
20 1,4-benz-oxazin-2-yl)acetic acid, the lactose and half the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate are added,
25 carefully mixed and processed into tablets.

Example 7

- Intravenous infusion 1-10 mg/ml. An intravenous infusion pharmaceutical
30 preparation can be manufactured by dissolving 50 mg of (4-phenyl-6-[[3-(2-pyridinylamino)butanoyl]amino]-3,4-dihydro-2H-1,4-benzoxazin-2-yl)acetic acid in water for injection (1000 ml) and sealing glass ampoules of 1-10 ml.
Prior to infusion, the obtained solution can be diluted according to the common

practice, and stored and/or delivered in glass, polypropylene, polyolefin or polyethylene-lined equipment.

2025-01-01 10:00:00